Key Points President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.Lilly's margins could be negatively affected if the company absorbs the higher costs.However, any ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly and Co's stock. This analysis reveals shifts in analysts' expectations over time.

Overall, Eli Lilly posted a solid Q2 and that also reflects in its stock price move. However, we think it’s appropriately valued at levels of over $900.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eli Lilly (NYSE: LLY) may not have been the top-performing large-cap pharmaceutical stock, but its performance this year is nothing ...

Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook leads to investor concerns. Read more here.

Eli Lilly (LLY 0.40%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.